Abrégé

Provided are chimeric oncolytic adenoviruses simultaneously expressing IL-12, IFN-γ, and CCL5, and an application thereof in tumor treatment. A capsid protein hexon of the oncolytic adenovirus is formed from chimerizing hexon sequences of the two serotype viruses Ad5 and Ad48, and a fiber protein is formed from chimerizing fiber sequences of the two serotype viruses Ad5 and Ad11. The chimeric oncolytic adenovirus can activate intrinsic anti-cancer activity of a variety of viral structural proteins, the ability to infect tumor cells is increased while also ensuring that the virus itself avoids interception from pre-existing neutralizing antibodies and adhesion and uptake of hepatocytes, and an effect of killing cancer cells is enhanced.

Classes IPC  ?

• A61K 35/761 - Adénovirus
• A61K 38/19 - CytokinesLymphokinesInterférons
• A61K 38/20 - Interleukines
• A61K 38/21 - Interférons
• A61P 35/00 - Agents anticancéreux

Abrégé

Provided are a chimeric oncolytic adenovirus simultaneously expressing IL-12, IFN-γ, and CCL5, and an application thereof in tumor treatment. A capsid protein hexon of the oncolytic adenovirus is formed from chimerizing hexon sequences of the two serotype viruses Ad5 and Ad48, and a fiber protein is formed from chimerizing fiber sequences of the two serotype viruses Ad5 and Ad11. The chimeric oncolytic adenovirus can activate intrinsic anti-cancer activity of a variety of viral structural proteins, the ability to infect tumor cells is increased while also ensuring that the virus itself avoids interception from pre-existing neutralizing antibodies and adhesion and uptake of hepatocytes, and an effect of killing cancer cells is enhanced.

Classes IPC  ?

• C12N 7/01 - Virus, p. ex. bactériophages, modifiés par l'introduction de matériel génétique étranger
• C12N 15/24 - Interleukines
• C12N 15/23 - Gamma-interférons
• C12N 15/19 - InterféronsLymphokinesCytokines
• C12N 15/34 - Protéines de virus à ADN
• A61K 35/761 - Adénovirus
• A61K 38/20 - Interleukines
• A61K 38/21 - Interférons
• A61K 38/19 - CytokinesLymphokinesInterférons
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• A61P 35/00 - Agents anticancéreux
• A61P 35/04 - Agents anticancéreux spécifiques pour le traitement des métastases
• C12R 1/93 - Virus des animaux

Abrégé

A fast and accurate three-plasmid oncolytic adenovirus recombinant packaging system Ad5MixPlus and an application thereof are provided. The system is composed of three adenovirus recombinant plasmids. The core technology of the system is that two sets of different site recombination sequences are skillfully loaded on a first 5-type adenovirus right arm backbone plasmid large vector, then two small shuttle plasmids respectively provide a right arm-modified Hexon/E3/Fiber sequence and an E1a expression cassette controlled by a left arm tumor-specific promoter, and the difficulties and obstacles to the modification of the adenovirus backbone large vector are overcome. After two rounds of site-specific recombination, the ideal oncolytic adenovirus is packaged accurately and quickly.

Classes IPC  ?

• C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
• C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales

Abrégé

A fast and accurate three-plasmid oncolytic adenovirus recombinant packaging system Ad5MixPlus and an application thereof. The system is composed of three adenovirus recombinant plasmids. The core technology of the system is that two sets of different site recombination sequences are skillfully loaded on a first 5-type adenovirus right arm backbone plasmid large vector, then two small shuttle plasmids respectively provide a right arm-modified Hexon/E3/Fiber sequence and an E1a expression cassette controlled by a left arm tumor-specific promoter, and the difficulties and obstacles to the modification of the adenovirus backbone large vector are overcome. After two rounds of site-specific recombination, the ideal oncolytic adenovirus is packaged accurately and quickly. A virus recombinant packaging process is simplified and quickened, a challenging problem of the modification of the adenovirus backbone large vector is solved, and the required oncolytic adenovirus can be rapidly recombined and screened; the system is very suitable for industrialization needs, and the packaged oncolytic adenovirus has significant anti-tumor activity.

Classes IPC  ?

• C12N 15/861 - Vecteurs adénoviraux
• A61K 35/761 - Adénovirus
• A61P 35/00 - Agents anticancéreux